Literature DB >> 24674691

Saccharomyces cerevisiae fungemia, a possible consequence of the treatment of Clostridium difficile colitis with a probioticum.

I Santino1, A Alari1, S Bono2, E Teti3, M Marangi3, A Bernardini4, L Magrini4, S Di Somma4, A Teggi3.   

Abstract

The yeast Saccharomyces boulardii is a biotherapeutic agent used for the prevention and treatment of several gastrointestinal diseases, such as diarrhoea caused by Clostridium difficile, in addition to the antibiotic therapy. In this study we report a case of Saccharomyces cerevisiae fungemia in a patient with Clostridium difficile-associated diarrhoea (CDAD) treated orally with S. boulardii in association with vancomycin. The identification of the S. cerevisiae was confirmed by molecular technique. Fungemia is a rare, but a serious complication to treatment with probiotics. We believe it is important to remind the clinicians of this risk when prescribing probiotics, especially to immunocompromised patients.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24674691     DOI: 10.1177/039463201402700120

Source DB:  PubMed          Journal:  Int J Immunopathol Pharmacol        ISSN: 0394-6320            Impact factor:   3.219


  14 in total

Review 1.  Risk and safety of probiotics.

Authors:  Shira Doron; David R Snydman
Journal:  Clin Infect Dis       Date:  2015-05-15       Impact factor: 9.079

2.  Therapeutic Manipulation of the Microbiome in IBD: Current Results and Future Approaches.

Authors:  Jonathan J Hansen; R Balfour Sartor
Journal:  Curr Treat Options Gastroenterol       Date:  2015-03

Review 3.  Probiotics for the prevention of Hirschsprung-associated enterocolitis.

Authors:  Fan Mei; Mei Wu; Li Zhao; Kaiyan Hu; Qianqian Gao; Fei Chen; Joey Sw Kwong; Yanan Wang; Xi Ping Shen; Bin Ma
Journal:  Cochrane Database Syst Rev       Date:  2022-04-26

Review 4.  Probiotics, Photobiomodulation, and Disease Management: Controversies and Challenges.

Authors:  Laura Marinela Ailioaie; Gerhard Litscher
Journal:  Int J Mol Sci       Date:  2021-05-06       Impact factor: 5.923

Review 5.  Vaccine against Helicobacter pylori: Inevitable approach.

Authors:  Amin Talebi Bezmin Abadi
Journal:  World J Gastroenterol       Date:  2016-03-21       Impact factor: 5.742

6.  Saccharomyces cerevisiae var. boulardii fungemia following probiotic treatment.

Authors:  Marcelo C Appel-da-Silva; Gabriel A Narvaez; Leandro R R Perez; Laura Drehmer; Jairo Lewgoy
Journal:  Med Mycol Case Rep       Date:  2017-07-25

7.  Experience with Saccharomyces boulardii Probiotic in Oncohaematological Patients.

Authors:  Beata Sulik-Tyszka; Emilian Snarski; Magda Niedźwiedzka; Małgorzata Augustyniak; Thorvald Nilsen Myhre; Anna Kacprzyk; Ewa Swoboda-Kopeć; Marta Roszkowska; Jadwiga Dwilewicz-Trojaczek; Wiesław Wiktor Jędrzejczak; Marta Wróblewska
Journal:  Probiotics Antimicrob Proteins       Date:  2018-06       Impact factor: 4.609

8.  Saccharomyces cerevisiae fungemia in a critically ill patient with acute cholangitis and long term probiotic use.

Authors:  Mustafa Fadhel; Swapnil Patel; Edward Liu; Michael Levitt; Arif Asif
Journal:  Med Mycol Case Rep       Date:  2018-11-12

9.  Saccharomyces: A Friend or Foe in ICU (A Case Report with Solution).

Authors:  Prasoon Gupta; Y P Singh; Akhil Taneja
Journal:  Indian J Crit Care Med       Date:  2019-09

10.  [Saccharomyces cerevisiae, is a yeast cell more and more involved in urinary tract infections: about 3 cases].

Authors:  Mohamed Zaïd Saoud; Mustapha Rhatous; Samira El Mire; Mohammed Lyagoubi; Sarra Aoufi
Journal:  Pan Afr Med J       Date:  2020-03-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.